{"nctId":"NCT00753948","briefTitle":"Exhaled Levels of Nitric Oxide","startDateStruct":{"date":"2006-12"},"conditions":["Tetraplegia","Asthma"],"count":23,"armGroups":[{"label":"Chronic Tetraplegia","type":"EXPERIMENTAL","interventionNames":["Drug: N-Nitro L-arginine-methylester (L-NAME)"]},{"label":"Mild Asthma","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: N-Nitro L-arginine-methylester (L-NAME)"]},{"label":"Healthy Control","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: N-Nitro L-arginine-methylester (L-NAME)"]}],"interventions":[{"name":"N-Nitro L-arginine-methylester (L-NAME)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Written informed consent.\n2. Age between 18 and 65 years.\n3. Able-bodied individuals, persons with mild asthma or individuals with tetraplegia for at least one year of duration.\n4. Able to perform acceptable pulmonary function tests and follow procedures.\n\nExclusion Criteria:\n\n1. coronary artery disease;\n2. active cigarette smokers or previous smokers who stopped \\<5 years ago;\n3. MI or stroke within 3 months;\n4. moderate to severe reduction in lung function defined as FEV1 \\< 70 % predicted (except in individuals with tetraplegia);\n5. hypertension;\n6. medications known to affect the cardiovascular system;\n7. pregnancy\n8. current use of cholinesterase medication; and\n9. lack of mental capacity to give informed consent Group specific exclusion criteria for\n\nAsthmatic subjects:\n\n1. Moderate to severe disease as per spirometric indices;\n2. testing within 48 hours of last administration of long acting inhaled bronchodilator;\n3. testing within 7 days of last administration of glucocorticoids;\n4. testing within \\> 24 hours since last administration of leukotriene modifiers; and\n5. testing within 8 hours of last administration of a short acting bronchodilator medication","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Exhaled Levels of Nitric Oxide","description":"Nitric Oxide was measured applying a real time technique for measurement of Nitric Oxide in Exhaled Breath Condensate. Elevated Nitric Oxide in exhalate is a measure of elevated production of NO in conditions such as underlying inflammation and/or oxidative stress. Exhaled NO was reported as the mean of three values within 10% of each other.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.27","spread":"4.96"},{"groupId":"OG001","value":"19.83","spread":"8.15"},{"groupId":"OG002","value":"15.025","spread":"9.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.70","spread":"3.14"},{"groupId":"OG001","value":"5.56","spread":"2.93"},{"groupId":"OG002","value":"4.07","spread":"3.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.04","spread":"2.23"},{"groupId":"OG001","value":"5.73","spread":"3.70"},{"groupId":"OG002","value":"3.71","spread":"3.46"}]}]}]},{"type":"SECONDARY","title":"Specific Airway Conductance (sGaw) as Measured by Plethysmography","description":"Specific airway conductance (sGaw) is the airway conductance relative to lung volume because it takes into account the important effect of lung volume on airway resistance, it is a useful index of bronchomotor tone.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.164","spread":"0.071"},{"groupId":"OG001","value":"0.336","spread":"0"},{"groupId":"OG002","value":"0.197","spread":"0.043"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.218","spread":"0.093"},{"groupId":"OG001","value":"0.315","spread":"0"},{"groupId":"OG002","value":"0.196","spread":"0.047"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.207","spread":"0.094"},{"groupId":"OG001","value":"0.345","spread":"0"},{"groupId":"OG002","value":"0.197","spread":"0.043"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":[]}}}